Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics

作者：Wang, Hai-yi; Su, Zi-hua; Xu, Xiao; Huang, Ning; Sun, Zhi-peng; Wang, Ying-wei; Li, Lu; Guo, Ai-tao; Chen, Xin; Ma, Xin; Ma, Lin; Ye, Hui-yi^*

来源：Scientific Reports, 2017, 7(1): 3117.

DOI：10.1038/s41598-017-03376-7

• ARTERIAL INPUT FUNCTION
• CELL CARCINOMA
• MINIMAL FAT
• ANGIOMYOLIPOMA
• REGISTRATION
• ONCOCYTOMA
• PARAMETERS
• FEATURES
• MASSES
• FORM

Preoperative renal tumor subtype differentiation is important for radiology and urology in clinical practice. Pharmacokinetic data (K-trans & V-e, etc.) derived from dynamic contrast-enhanced MRI (DCE-MRI) have been used to investigate tumor vessel permeability. In this prospective study on DCE-MRI pharmacokinetic studies, we enrolled patients with five common renal tumor subtypes: clear cell renal cell carcinoma (ccRCC; n = 65), papillary renal cell carcinoma (pRCC; n = 12), chromophobic renal cell carcinoma (cRCC; n = 9), uroepithelial carcinoma (UEC; n = 14), and fat-poor angiomyolipoma (fpAML; n = 10). The results show that Ktrans of ccRCC, pRCC, cRCC, UEC and fpAML (0.459 +/- 0.190 min(-1), 0.206 +/- 0.127 min(-1), 0.311 +/- 0.111 min(-1), 0.235 +/- 0.116 min(-1), 0.511 +/- 0.159 min(-1), respectively) were different, but Ve was not. Ktrans could distinguish ccRCC from non-ccRCC (pRCC & cRCC) with a sensitivity of 76.9% and a specificity of 71.4%, respectively, as well as to differentiate fpAML from non-ccRCC with a sensitivity of 100% and a specificity of 76.2%, respectively. Our findings suggest that DCE-MRI pharmacokinetics are promising for differential diagnosis of renal tumors, especially for RCC subtype characterization and differentiation between fpAML and non-ccRCC, which may facilitate the treatment of renal tumors.

• 出版日期2017-6-8
• 单位中国人民解放军总医院